Why the study?
Multiple analytical methods have been published for determining ticagrelor in pharmaceuticals and biological materials, prompting a systematic survey of these techniques.
Key points are not available for this paper at this time.
Design
Systematic review
Multiple ticagrelor assays now available; leaves open standardization for routine clinical or trial use.
Ticagrelor is an orally administered platelet aggregation inhibitor with a cyclopentyl-triazolopyrimidine structure; it is a selective reversible P2Y12 receptor antagonist, which prevents P2Y12-mediated and ADP-mediated platelet activation and aggregation. It is used to reduce the rate of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome or history of myocardial infarction. Several analytical methods have been published for the determination of ticagrelor in pharmaceuticals and biological materials by spectrophotometry, high-performance liquid chromatography with ultraviolet detection and liquid chromatography coupled with tandem mass spectrometry. The purpose of the current review is to provide a systematic survey of the analytical techniques used for the determination of ticagrelor since its introduction in therapy until today.
No takes yet. Share an insight, caveat, or question.
Kelemen et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: